135 related articles for article (PubMed ID: 30025155)
1. Activin type IIB receptor blockade does not limit adenosine triphosphate supply in mouse skeletal muscle in Vivo.
Béchir N; Pecchi É; Vilmen C; Bernard M; Bendahan D; Giannesini B
Muscle Nerve; 2018 Dec; 58(6):834-842. PubMed ID: 30025155
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo.
Béchir N; Pecchi É; Relizani K; Vilmen C; Le Fur Y; Bernard M; Amthor H; Bendahan D; Giannesini B
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E539-49. PubMed ID: 26837807
[TBL] [Abstract][Full Text] [Related]
3. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo.
Béchir N; Pecchi E; Vilmen C; Le Fur Y; Amthor H; Bernard M; Bendahan D; Giannesini B
FASEB J; 2016 Oct; 30(10):3551-3562. PubMed ID: 27416839
[TBL] [Abstract][Full Text] [Related]
4. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
5. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
6. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.
Pistilli EE; Bogdanovich S; Goncalves MD; Ahima RS; Lachey J; Seehra J; Khurana T
Am J Pathol; 2011 Mar; 178(3):1287-97. PubMed ID: 21356379
[TBL] [Abstract][Full Text] [Related]
7. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.
Relizani K; Mouisel E; Giannesini B; Hourdé C; Patel K; Morales Gonzalez S; Jülich K; Vignaud A; Piétri-Rouxel F; Fortin D; Garcia L; Blot S; Ritvos O; Bendahan D; Ferry A; Ventura-Clapier R; Schuelke M; Amthor H
Mol Ther; 2014 Aug; 22(8):1423-1433. PubMed ID: 24861054
[TBL] [Abstract][Full Text] [Related]
8. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.
Pistilli EE; Bogdanovich S; Mosqueira M; Lachey J; Seehra J; Khurana TS
Am J Physiol Regul Integr Comp Physiol; 2010 Jan; 298(1):R96-R103. PubMed ID: 19864340
[TBL] [Abstract][Full Text] [Related]
10. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.
Koncarevic A; Cornwall-Brady M; Pullen A; Davies M; Sako D; Liu J; Kumar R; Tomkinson K; Baker T; Umiker B; Monnell T; Grinberg AV; Liharska K; Underwood KW; Ucran JA; Howard E; Barberio J; Spaits M; Pearsall S; Seehra J; Lachey J
Endocrinology; 2010 Sep; 151(9):4289-300. PubMed ID: 20573726
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice.
Lawlor MW; Read BP; Edelstein R; Yang N; Pierson CR; Stein MJ; Wermer-Colan A; Buj-Bello A; Lachey JL; Seehra JS; Beggs AH
Am J Pathol; 2011 Feb; 178(2):784-93. PubMed ID: 21281811
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism.
Fournier B; Murray B; Gutzwiller S; Marcaletti S; Marcellin D; Bergling S; Brachat S; Persohn E; Pierrel E; Bombard F; Hatakeyama S; Trendelenburg AU; Morvan F; Richardson B; Glass DJ; Lach-Trifilieff E; Feige JN
Mol Cell Biol; 2012 Jul; 32(14):2871-9. PubMed ID: 22586266
[TBL] [Abstract][Full Text] [Related]
13. Lack of myostatin impairs mechanical performance and ATP cost of contraction in exercising mouse gastrocnemius muscle in vivo.
Giannesini B; Vilmen C; Amthor H; Bernard M; Bendahan D
Am J Physiol Endocrinol Metab; 2013 Jul; 305(1):E33-40. PubMed ID: 23632633
[TBL] [Abstract][Full Text] [Related]
14. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
15. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
Morrison BM; Lachey JL; Warsing LC; Ting BL; Pullen AE; Underwood KW; Kumar R; Sako D; Grinberg A; Wong V; Colantuoni E; Seehra JS; Wagner KR
Exp Neurol; 2009 Jun; 217(2):258-68. PubMed ID: 19285073
[TBL] [Abstract][Full Text] [Related]
16. Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Liu M; Hammers DW; Barton ER; Sweeney HL
PLoS One; 2016; 11(11):e0166803. PubMed ID: 27870893
[TBL] [Abstract][Full Text] [Related]
17. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
18. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
19. Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition.
Goncalves MD; Pistilli EE; Balduzzi A; Birnbaum MJ; Lachey J; Khurana TS; Ahima RS
PLoS One; 2010 Sep; 5(9):e12707. PubMed ID: 20856813
[TBL] [Abstract][Full Text] [Related]
20. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
